Jeffry Lansman
Jeffry B.
≈ 4 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Jeffry B. Lansman (born 19511, in Miami Beach, Florida) is an American cellular and molecular physiologist, pharmacologist, and academic. He is Professor Emeritus of Cellular and Molecular Pharmacology in the School of Medicine of the University of California, San Francisco, and is a member of UCSF's Weill Institute for Neurosciences and Cardiovascular Research Institute.
He is the founder and chief executive officer of PraecisAi.corp, a precision cardiovascular diagnostics company using advanced AI methods to bring high level cardiovascular care to rural and resource-limited communities globally. He is also the founder and chief scientific officer of Turex Marine BioPharma.
Early life
Lansman is known for biophysical research on ion channels in nerve and muscle and their role in disease pathogenesis. As a postdoctoral fellow at Yale School of Medicine with Richard W. Tsien and Peter Hess, he co-authored the defining characterization of the L- and T-type voltage-gated calcium channels in cardiac muscle and determined the mechanism of action of dihydropyridine drugs, used in cardiovascular disease.
At UCSF, his laboratory established mechanosensitive ion channels as a driver of pathological calcium loading in Duchenne muscular dystrophy and identified TRPV4 as a molecular component of those channels.…
Jeffry B. Lansman (born 1951, in Miami Beach, Florida) is an American cellular and molecular physiologist, pharmacologist, and academic. He is Professor Emeritus of Cellular and Molecular Pharmacology in the School of Medicine of the University of California, San Francisco, and is a member of UCSF's Weill Institute for Neurosciences and Cardiovascular Research Institute.
He is the founder and chief executive officer of PraecisAi.corp, a precision cardiovascular diagnostics company using advanced AI methods to bring high level cardiovascular care to rural and resource-limited communities globally. He is also the founder and chief scientific officer of Turex Marine BioPharma.
Lansman is known for biophysical research on ion channels in nerve and muscle and their role in disease pathogenesis. As a postdoctoral fellow at Yale School of Medicine with Richard W. Tsien and Peter Hess, he co-authored the defining characterization of the L- and T-type voltage-gated calcium channels in cardiac muscle and determined the mechanism of action of dihydropyridine drugs, used in cardiovascular disease.
At UCSF, his laboratory established mechanosensitive ion channels as a driver of pathological calcium loading in Duchenne muscular dystrophy and identified TRPV4 as a molecular component of those channels. He is a seven-time recipient of the Long Prize Teacher of the Year and the Long Prize for excellence in Teaching at the UCSF School of Pharmacy and a two-time Teacher of the Year of the American Association of Colleges of Pharmacy.
From 2013 to 2016 he chaired the University of California system-wide Committee on Privilege and Tenure, the Academic Senate body responsible for faculty grievance and disciplinary adjudication across all ten UC campuses.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1373061938 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “Jeffry Lansman” date of birth (×1) · confidence 0.95 revision URL